Alembic Pharmaceuticals receives USFDA tentative approval for 45 mg Binimetinib tablets

What Alembic Pharmaceuticals announced

On 19 June 2026, Alembic Pharmaceuticals Limited (BSE: 533573, NSE: APLLTD) filed a press release with the stock exchanges stating that it has received tentative approval from the United States Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Binimetinib tablets, 45 mg. The announcement was made under Regulation 30 (LODR) and is recorded as a press‑release filing.

"Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Binimetinib Tablets, 45 mg."

The tentative approval follows an earlier USFDA tentative nod for the 15 mg strength of the same molecule, confirming that the 45 mg tablet meets the agency’s standards for safety, efficacy, and bio‑equivalence to the reference listed drug (RLD), Mektovi 15 mg tablets from Array.

Details of the USFDA tentative approval

The USFDA’s tentative approval is granted for ANDAs that satisfy the agency’s requirements but cannot be marketed in the United States until a final approval is issued. Alembic’s ANDA for Binimetinib 45 mg contains a Paragraph IV certification under the Hatch‑Waxman Act, indicating that the company believes the patent claims of the RLD are invalid, unenforceable, or not applicable. Because Alembic is the sole first applicant to file a Paragraph IV‑certified ANDA for this strength, it stands to receive up to 180 days of generic marketing exclusivity once the USFDA issues a final approval.

Binimetinib is a kinase inhibitor used in combination with encorafenib for two specific oncology indications:

• Unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
• Metastatic non‑small cell lung cancer (NSCLC) with a BRAF V600E mutation.

According to IQVIA, the estimated US market size for Binimetinib tablets (all strengths) was US$ 259 million for the twelve‑month period ending March 2026. The 45 mg strength is expected to capture a share of this market, especially in combination regimens where a higher dose may be clinically preferred.

Alembic’s ANDA track record and product pipeline

Alembic highlighted that it now has a cumulative total of 242 USFDA ANDA approvals, comprising 222 final approvals and 20 tentative approvals. This record underscores the company’s long‑standing focus on generic drug development and its capability to navigate US regulatory pathways.

The earlier tentative approval for Binimetinib 15 mg was announced in a separate filing, and together the two strengths broaden Alembic’s offering in the oncology generic space. The company’s vertically integrated R&D and manufacturing facilities, all USFDA‑approved, enable it to produce high‑quality generic products at scale.

Key facts at a glance

Why this matters for investors

The tentative approval adds a new, high‑value oncology generic to Alembic’s portfolio. Oncology generics typically command higher pricing power and reimbursement rates compared with many other therapeutic classes. The potential 180‑day exclusivity can provide a protected revenue window before other generic competitors enter the market, which may translate into incremental cash flows for the company.

Alembic’s large existing ANDA base (242 approvals) demonstrates its ability to secure and commercialise US‑based generic products. The addition of Binimetinib 45 mg expands its presence in the BRAF‑targeted therapy segment, a niche with limited generic competition. While the filing does not disclose launch timelines, pricing, or projected sales, the disclosed US$ 259 million market estimate offers a quantitative reference for the size of the opportunity.

From a regulatory perspective, the Paragraph IV certification signals Alembic’s confidence in challenging any remaining patent protections on the reference product. Successful navigation of this pathway can enhance the company’s reputation among US regulators and may facilitate smoother approvals for future ANDAs.

Investors should note that tentative approval does not permit commercial sales in the United States until a final approval is granted. The timeline for final approval depends on USFDA review, any potential patent litigation, and the company’s submission of any outstanding data. Consequently, any revenue impact will materialise only after those steps are completed.

Conclusion

Alembic Pharmaceuticals has secured USFDA tentative approval for its 45 mg Binimetinib tablet, complementing an earlier 15 mg approval and positioning the firm for a possible 180‑day exclusivity period upon final approval. The drug targets high‑need oncology indications and sits within a US market estimated at $259 million. While the filing confirms Alembic’s robust ANDA track record, the commercial benefits will depend on the subsequent final approval and the company’s launch strategy, details of which were not disclosed in the announcement.